Age-associated B cells predict impaired humoral immunity after COVID-19 vaccination in patients receiving immune checkpoint blockade
© 2023. The Author(s)..
Age-associated B cells (ABC) accumulate with age and in individuals with different immunological disorders, including cancer patients treated with immune checkpoint blockade and those with inborn errors of immunity. Here, we investigate whether ABCs from different conditions are similar and how they impact the longitudinal level of the COVID-19 vaccine response. Single-cell RNA sequencing indicates that ABCs with distinct aetiologies have common transcriptional profiles and can be categorised according to their expression of immune genes, such as the autoimmune regulator (AIRE). Furthermore, higher baseline ABC frequency correlates with decreased levels of antigen-specific memory B cells and reduced neutralising capacity against SARS-CoV-2. ABCs express high levels of the inhibitory FcγRIIB receptor and are distinctive in their ability to bind immune complexes, which could contribute to diminish vaccine responses either directly, or indirectly via enhanced clearance of immune complexed-antigen. Expansion of ABCs may, therefore, serve as a biomarker identifying individuals at risk of suboptimal responses to vaccination.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
---|---|
Enthalten in: |
Nature communications - 14(2023), 1 vom: 27. Juni, Seite 3292 |
Sprache: |
Englisch |
---|
Links: |
---|
Themen: |
Antibodies, Viral |
---|
Anmerkungen: |
Date Completed 29.06.2023 Date Revised 13.03.2024 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1038/s41467-023-38810-0 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM358709725 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM358709725 | ||
003 | DE-627 | ||
005 | 20240313233511.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s41467-023-38810-0 |2 doi | |
028 | 5 | 2 | |a pubmed24n1326.xml |
035 | |a (DE-627)NLM358709725 | ||
035 | |a (NLM)37369658 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Yam-Puc, Juan Carlos |e verfasserin |4 aut | |
245 | 1 | 0 | |a Age-associated B cells predict impaired humoral immunity after COVID-19 vaccination in patients receiving immune checkpoint blockade |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 29.06.2023 | ||
500 | |a Date Revised 13.03.2024 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023. The Author(s). | ||
520 | |a Age-associated B cells (ABC) accumulate with age and in individuals with different immunological disorders, including cancer patients treated with immune checkpoint blockade and those with inborn errors of immunity. Here, we investigate whether ABCs from different conditions are similar and how they impact the longitudinal level of the COVID-19 vaccine response. Single-cell RNA sequencing indicates that ABCs with distinct aetiologies have common transcriptional profiles and can be categorised according to their expression of immune genes, such as the autoimmune regulator (AIRE). Furthermore, higher baseline ABC frequency correlates with decreased levels of antigen-specific memory B cells and reduced neutralising capacity against SARS-CoV-2. ABCs express high levels of the inhibitory FcγRIIB receptor and are distinctive in their ability to bind immune complexes, which could contribute to diminish vaccine responses either directly, or indirectly via enhanced clearance of immune complexed-antigen. Expansion of ABCs may, therefore, serve as a biomarker identifying individuals at risk of suboptimal responses to vaccination | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
650 | 7 | |a COVID-19 Vaccines |2 NLM | |
650 | 7 | |a Antigen-Antibody Complex |2 NLM | |
650 | 7 | |a Antibodies, Viral |2 NLM | |
700 | 1 | |a Hosseini, Zhaleh |e verfasserin |4 aut | |
700 | 1 | |a Horner, Emily C |e verfasserin |4 aut | |
700 | 1 | |a Gerber, Pehuén Pereyra |e verfasserin |4 aut | |
700 | 1 | |a Beristain-Covarrubias, Nonantzin |e verfasserin |4 aut | |
700 | 1 | |a Hughes, Robert |e verfasserin |4 aut | |
700 | 1 | |a Lulla, Aleksei |e verfasserin |4 aut | |
700 | 1 | |a Rust, Maria |e verfasserin |4 aut | |
700 | 1 | |a Boston, Rebecca |e verfasserin |4 aut | |
700 | 1 | |a Ali, Magda |e verfasserin |4 aut | |
700 | 1 | |a Fischer, Katrin |e verfasserin |4 aut | |
700 | 1 | |a Simmons-Rosello, Edward |e verfasserin |4 aut | |
700 | 1 | |a O'Reilly, Martin |e verfasserin |4 aut | |
700 | 1 | |a Robson, Harry |e verfasserin |4 aut | |
700 | 1 | |a Booth, Lucy H |e verfasserin |4 aut | |
700 | 1 | |a Kahanawita, Lakmini |e verfasserin |4 aut | |
700 | 1 | |a Correa-Noguera, Andrea |e verfasserin |4 aut | |
700 | 1 | |a Favara, David |e verfasserin |4 aut | |
700 | 1 | |a Ceron-Gutierrez, Lourdes |e verfasserin |4 aut | |
700 | 1 | |a Keller, Baerbel |e verfasserin |4 aut | |
700 | 1 | |a Craxton, Andrew |e verfasserin |4 aut | |
700 | 1 | |a Anderson, Georgina S F |e verfasserin |4 aut | |
700 | 1 | |a Sun, Xiao-Ming |e verfasserin |4 aut | |
700 | 1 | |a Elmer, Anne |e verfasserin |4 aut | |
700 | 1 | |a Saunders, Caroline |e verfasserin |4 aut | |
700 | 1 | |a Bermperi, Areti |e verfasserin |4 aut | |
700 | 1 | |a Jose, Sherly |e verfasserin |4 aut | |
700 | 1 | |a Kingston, Nathalie |e verfasserin |4 aut | |
700 | 1 | |a Mulroney, Thomas E |e verfasserin |4 aut | |
700 | 1 | |a Piñon, Lucia P G |e verfasserin |4 aut | |
700 | 0 | |a CITIID-NIHR COVID−19 BioResource Collaboration |e verfasserin |4 aut | |
700 | 1 | |a Chapman, Michael A |e verfasserin |4 aut | |
700 | 1 | |a Grigoriadou, Sofia |e verfasserin |4 aut | |
700 | 1 | |a MacFarlane, Marion |e verfasserin |4 aut | |
700 | 1 | |a Willis, Anne E |e verfasserin |4 aut | |
700 | 1 | |a Patil, Kiran R |e verfasserin |4 aut | |
700 | 1 | |a Spencer, Sarah |e verfasserin |4 aut | |
700 | 1 | |a Staples, Emily |e verfasserin |4 aut | |
700 | 1 | |a Warnatz, Klaus |e verfasserin |4 aut | |
700 | 1 | |a Buckland, Matthew S |e verfasserin |4 aut | |
700 | 1 | |a Hollfelder, Florian |e verfasserin |4 aut | |
700 | 1 | |a Hyvönen, Marko |e verfasserin |4 aut | |
700 | 1 | |a Döffinger, Rainer |e verfasserin |4 aut | |
700 | 1 | |a Parkinson, Christine |e verfasserin |4 aut | |
700 | 1 | |a Lear, Sara |e verfasserin |4 aut | |
700 | 1 | |a Matheson, Nicholas J |e verfasserin |4 aut | |
700 | 1 | |a Thaventhiran, James E D |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 14(2023), 1 vom: 27. Juni, Seite 3292 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
773 | 1 | 8 | |g volume:14 |g year:2023 |g number:1 |g day:27 |g month:06 |g pages:3292 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-023-38810-0 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 14 |j 2023 |e 1 |b 27 |c 06 |h 3292 |